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Abstract
Introduction—The epidemiology of tamoxifen and venous thromboembolism (VTE) is not well
understood, and most data on tamoxifen toxicity are from adjuvant clinical trials. This study
examined the relationship between the duration of tamoxifen use in female patients with breast
cancer and the risk of VTE in a large population-based setting.
Materials and Methods—Retrospective electronic data extraction on tamoxifen utilization was
undertaken among a cohort of 3572 women with breast cancer seen at Marshfield Clinic between
January 1, 1994 and June 31, 2009. Observational follow-up extended until February, 2010.
Results—On initial exposure to tamoxifen, women had a clustering of VTE events. Cox
proportional hazards regression, adjusting for multiple clinically-important covariates including
age, body mass index, cancer stage, and concurrent diabetes, demonstrated that as use of
tamoxifen continued in those without earlier VTE events, risk of subsequent VTE gradually
increased, albeit at a lower rate (hazard ratio per year of tamoxifen duration=1.225, P <0.0001).
Conclusions—In our study population, initiating tamoxifen coincided with an initial clustering
of VTE events, with risks due specifically to tamoxifen, increasing during continued exposure.
Evidence suggested that the VTE clustering occurred in high risk individuals at initiation of
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tamoxifen therapy. Careful selection of patients for whom tamoxifen therapy is appropriate based
on susceptibility to VTE is thus required prior to initiation of therapy.
Keywords
Breast cancer; DVT; Tamoxifen; VTE
Introduction
Tamoxifen is a selective estrogen receptor modulator approved by the US Food and Drug
Administration in 1977, and it remains the most prescribed hormonal/endocrine therapy for
treatment and prevention of breast cancer. Tamoxifen use improves mortality rates for those
with estrogen receptor (ER) positive breast cancer and decreases breast cancer incidence
rates in high-risk women [1–5]. A review of all breast cancer risk reduction trials estimated
a 38% reduction in estrogen-positive breast cancer incidence [6]. Tamoxifen has been
associated with significant side effects and complications, including increased risk of
endometrial cancer, deep vein thrombosis (DVT), and pulmonary embolism (PE) [7–12].
An estimated 207,090 women were diagnosed with breast cancer in the United States in
2010, with 39,840 deaths attributed to the disease [13]. Despite the availability of newer
aromatase inhibitors, and more recently generic anastrazole, tamoxifen remains widely used
in pre-and post-menopausal women due to its ready availability, relatively low cost and
well-demonstrated efficacy. Data on potential tamoxifen-related complications in non-
clinical trial settings are scarce, despite more than three decades of tamoxifen use [14].
Previous findings from clinical trials are often invalidated as a consequence of reporting or
publication bias. In some studies non-significant findings may result in an underestimation
of absolute risk or an overestimation of risk due to unusually high incidence of a particular
health outcome [15]. Generally, reporting bias may result in underestimation of risk when
surveillance is limited due to an abbreviated follow-up period, which is characteristic of
many clinical trials. If an adverse event is not targeted as a primary outcome of a study or
has not been identified prior to the study, this may hinder accurate reporting of results.
Accurate risk estimation from these trials may also be limited by the inability to identify and
capture specific and important clinical characteristics.
A comprehensive study of tamoxifen use performed in a community practice setting may
provide wider generalizability than clinical trials. Our study design, from a community
health perspective, allowed us to identify patient risk characteristics associated with
tamoxifen use relative to length of tamoxifen treatment. The goal of this research project
was to better define the epidemiology of tamoxifen-related venous thromboembolism
(VTE). This research applied an evidence-based approach in a clinical setting to address a
critical clinical knowledge gap in the treatment and care of breast cancer patients.
Materials and methods
The study was approved by the Institutional Review Board of the Marshfield Clinic.
Marshfield Clinic is a large multi-specialty, multi-site group practice with regional centers
located throughout central and northern Wisconsin. In partnership with St. Joseph’s Hospital
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in the city of Marshfield, Marshfield Clinic has one of the oldest internally-developed
combined electronic medical records (EMRs) in the United States [16], with coded
diagnoses dating back to the early 1960’s and laboratory observations dating back to 1985.
The EMR data collected for clinical care are transferred daily into the Marshfield Clinic
Data Warehouse where they are available for approved research. The clinical EMR also
provides access to over 60 million free-text electronic clinical documents dating back to
1988.
Study population
The study population consisted of a cohort of 3572 female patients with breast cancer ≥18
years of age who were treated with tamoxifen at Marshfield Clinic. Eighteen percent of the
population was deceased. Among patients who died, only 15 terminated tamoxifen at the
time (n=3) or within one week of (n=12) of a VTE event (0.4%). Subjects were identified
through the Marshfield Clinic/St. Joseph’s Hospital Cancer Registry using International
Classification of Diseases for Oncology third revision (ICD-O-3) codes C50.0–C50.9 and/or
through the Marshfield Clinic EMR using International Classification of Diseases ninth
revision (ICD-9) codes 174.0–174.9, 175.0–175.9, 198.81, and 233.0. Dates of first
tamoxifen treatment ranged between the years 1994 and 2009. Follow-up data were
collected through interrogation of the EMR through February, 2010.
Data collection
The following data were extracted from the EMR as available for each subject: age, gender,
height, weight, body mass index (BMI), diagnosis of diabetes, use of statins and hormone
replacement therapy (HRT), blood pressure, lipid measures (low-density lipoprotein, high-
density lipoprotein, triglycerides, total cholesterol), stage of cancer at diagnosis, treatment
(tamoxifen dose, surgery, radiation, and chemotherapy), and dates of diagnoses for the
events of interest. The pivotal temporal reference point was the date of tamoxifen initiation,
and all subsequent patient measures were extracted from the EMR as close in time as
possible to that date.
Validation
Manual record review was used to validate various aspects of the electronic coding. Data for
261 tamoxifen subjects had been manually abstracted in a pilot study, and 242 of these
subjects (93%) were identified electronically for the current study. The remaining 19
subjects were excluded due to missing or uncertain tamoxifen coding in the electronic
record. In addition, cancer staging was obtained manually for 1329 subjects since these data
were not captured among registry data for a number of subjects.
Statistical analyses
Standard descriptive statistics were used to summarize important characteristics of the
tamoxifen cohort. The primary study outcomes were PE and DVT (i.e., VTE) subsequent to
tamoxifen treatment. The numbers of events were summarized by type, both prior and
subsequent to treatment, but subjects with prior events were excluded from Cox proportional
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hazards time-to-event analyses since new incident events may be difficult to distinguish in
the EMR, and since event risks are likely different for subjects with prevalent events.
In preliminary analyses, those without prevalent events were divided into quartiles (four
equal-sized groups) based on the duration of tamoxifen use observed during the study
period. By dividing patients into quartiles of duration of tamoxifen use, we were able to
group our patients based on increasing length of exposure to tamoxifen, and for each
duration group (quartile) time to VTE was measured from time of initiation of tamoxifen till
end of follow-up. The numbers of events subsequent to tamoxifen initiation were
summarized in each group for the first five years.
Proportional hazards (PH) analyses were also used to investigate potential confounding by
age and other established clinical risk factors. We checked the PH assumption for our
primary factor of interest (duration of tamoxifen) by dividing time into three intervals and
found no significant interaction of duration and time period (P=0.14). However, time in our
analyses is not “survival” per se, but rather time to the first venous event, with time being
censored at the most recent EMR observation date in those not having events. While it may
seem like the duration of tamoxifen and duration of follow-up are similar, in reality the
duration of follow-up is usually much greater. Thus, a patient discontinuing tamoxifen in
year 1 may still be followed up for 15 years. Since the relative risks for adverse events on a
drug may change with duration of exposure [17], the methods described below were used to
incorporate tamoxifen duration as a time-varying covariate in the time-to-event analyses. A
covariate, “years of use”, was defined as the duration of use in years, which was 0 at
initiation and increased until tamoxifen was stopped, at which time it equaled the total
duration of use and remained at that value until the end of the patient’s observation time.
The assumption of linearity in the effect of duration was investigated using restricted cubic
splines [18], but the spline adjustments were not statistically significant, and we report only
results for linear effects for age here. Results for the proportional hazards analyses were
obtained with and without adjustment for age and other established clinical risk factors. BMI
and hospitalizations were coded as categorical variables. For 19% of the cohort BMI was
unavailable, so in those cases overall mean value was used in categorization. Results from
the proportional hazards model were summarized with the estimated hazard ratio per year of
tamoxifen duration (HR) and 95% confidence limits, and the significance of these
comparisons was tested with Wald chi-square statistics.
Results
Descriptive values for the study population are shown in Tables 1 and 2. Patient median age
was 62; median BMI was 28.6 kg/m2 (which is considered “overweight”); median blood
pressure was borderline hypertensive, and median lipid measures were consistently within
normal or even optimal ranges. The latter finding, in conjunction with data indicating statin
use by 37% of subjects, indicated that lipid levels represented were in part clinically
normalized. Breast cancer stage was most frequently Stage 1 (45%); and 68.7% of subjects
had undergone surgery as a treatment option. DVT or PE prior to tamoxifen use occurred in
2.5% (92/3527). Among the 3435 women without prior DVT or PE, 8.4% (289/3435)
experienced DVT or PE after initiation of tamoxifen therapy. Among the 289 who had
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events after initiation of tamoxifen, the incidence in 25 women (8.7%) occurred within 5
days of last recorded tamoxifen exposure, while 136 women (47.1%) experienced
thromboembolic events sometime later following tamoxifen discontinuation.
Median duration of tamoxifen use by quartile was as follows: 1st Quartile 0.5 years, 2nd
Quartile 2.1 years, 3rd Quartile 4.1 years, and 4th Quartile 5.1 years. Fig. 1 shows the
cumulative 5-year incidence of VTE by quartile of duration of tamoxifen. This plot
demonstrates increased VTE risk at early time points in the first two quartiles compared to
the last two quartiles of duration of tamoxifen use.
If there is a lower incidence when a subject belongs to a longer duration group this could
suggest that tamoxifen protects against VTE. We actually found this (Fig. 1), but we know,
based on knowledge of the drug, that tamoxifen cannot possibly protect against VTE.
Rather, we conclude that this represents discontinuation of the drug early in the two shorter
duration groups because of clustering of VTE with onset of tamoxifen; thus, Fig. 1 does not
tell the full story (and thus is not our primary analysis) but serves to illustrate an important
point. We followed this up by an analysis that accounts for variability in duration of
tamoxifen use over time. Table 3 reports results of analyses using time-varying covariates to
model duration in the proportional hazards regression analysis of tamoxifen duration and
VTE hazard. The hazard ratio implies that at any given time, the odds that an event will
occur in those on longer duration of tamoxifen compared to another individual is
significantly greater (P <0.0001). Hazard ratios and associated P values showed little
variation with or without adjustment (all P values <0.0001). The reason for the apparent
discrepancy between results from the latter analysis (Table 3) and the analysis in Fig. 1 is
that a large subset of patients clustered around 0.5–2 years of tamoxifen treatment developed
VTE early on (Quartiles 1 and 2), while events appeared more widely distributed over time
for the remaining patients. In summary, overall early clustering following tamoxifen
initiation led to the appearance of a relatively higher event rate in an early period following
tamoxifen initiation (Fig. 1). Those that did not have an early event were then at increased
risk for a later event albeit at a lower rate, but this risk increased over time and was not
attenuated by the conventional risk factors for VTE.
Discussion
The clinical association between VTE and cancer is well established, with an overall risk for
VTE elevated 7-fold in patients with cancer. Notably, breast cancer is associated with one of
the lowest risks [4]. Based on the experiences of patients exposed to tamoxifen during the
past 30 years, epidemiological evidence suggests tamoxifen use is associated with an
increased incidence of VTE. Adjuvant hormonal therapy with tamoxifen is thought to
increase the risk for VTE, independent of the breast cancer diagnosis [4]. A recent
population-based study suggests that the first 2 years after the initiation of tamoxifen therapy
may be the most crucial time for monitoring VTE risk, particularly in older women [9], and
studies of chemoprophylaxis in women without a breast cancer diagnosis also suggest an
increased risk for PE and DVT with tamoxifen use [19]. The fact that some previous studies
report a “decrease” in risk of VTE over time with sustained use [9] is consistent with this
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clustering effect, but this issue remains understudied, and existing published reports on this
issue have not provided consistent conclusions.
Among our cohort of women exposed to tamoxifen, the rates of VTE over the same early
window of follow-up were clearly higher amongst those in the lower quartiles of duration of
tamoxifen use compared to those in the higher quartiles (Fig. 1). Simple analyses of
incidence seem to suggest that something has changed at the individual level. However, it is
in fact the population risk that has changed. The fact that many medication effects vary by
duration is well known [17,20]. Clustering of estrogenic effect or other side effects within
the first year or more of starting estrogen or tamoxifen, similar to our finding, has been
reported by others [9,21]. For example, summary estimates of endometrial cancer risk
among individuals on estrogen has also been reported to be higher within about a year or
more of starting estrogen [21].
Early clustering of events may be the result of a combination of VTE effect of tamoxifen
and conventional risk factors of VTE such as age, obesity, cancer stage, and immobilization
due to hospitalization. The fact that these early events could have occurred in those who
might have had more of such conventional risk factors of VTE is supported by data from the
literature. There is evidence of a link between atherosclerosis and VTEs which suggests that
tamoxifen triggers some of these common mechanistic pathways [2]. There is also evidence
that common VTE risk factors tend to be associated with the earlier development of VTE on
tamoxifen [7], similar to the effect reported for HRT [22]. It is therefore plausible that in
those individuals with risk factors, emergence of VTE following tamoxifen exposure occurs
early, while others without risk factors are at a considerably lower risk of VTE following
tamoxifen exposure. This explains the possible clustering effect of venous events occurring
in a subset of patients around the first 6 to 12 months on tamoxifen.
When duration of tamoxifen use was entered as a time-varying covariate in the proportional
hazards model, there was an apparent reversal in the trend, and the hazard of VTE events
was greater in those with persistent ongoing use over time. This discrepancy between the
analyses simply suggests that longer duration quartiles would have been ‘depleted’ of
patients at high risk for the VTE event, either through having the event itself and stopping
tamoxifen or through having warning symptoms leading to discontinuation before the event
occurred [17]. The effect works by changing the population at risk, and hence changing the
estimate at a population level even though nothing may be changed at an individual level
[17]. This is because the initial clustering leads to selection of a lower risk population on
tamoxifen in the later years. This might suggest that those on tamoxifen had lower rates of
VTE over time, but this conclusion would be erroneous, although such instances have
occurred in the literature [9,23]. In our study, those with longer duration of tamoxifen
utilization eventually showed higher event rates after adjusting for initial clustering that led
to discontinuation of tamoxifen. Adjustments for other clinical or demographic factors had
little effect on the results using duration as a variable length of exposure covariate,
indicating that long-term tamoxifen therapy itself remains an important independent factor
for increased thrombotic risk.
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There are several limitations to the present study. First, there was no truly unexposed control
group for comparison; all cohort members were “exposed” to tamoxifen for varying lengths
of time. This lack of a control group limited our ability to determine how the event risk may
change over time in the absence of tamoxifen. Secondly, data were not available on the
reason for tamoxifen discontinuation or precisely when discontinuation occurred, since our
data defaults to the last clinic verification of a prescription for tamoxifen. Therefore,
although there was not an absolute temporal sequence from VTE to tamoxifen
discontinuation in every case, the sequence was close enough to suggest that it was generally
the thromboembolic event itself that limited the duration of therapy, and the clustering we
demonstrated suggests that this is indeed the case. Furthermore, occurrence of
approximately a quarter of the events in the first year of follow-up supports our conclusions.
Conclusions
In our study population, tamoxifen use appeared to lead to a clustering of the VTE events at
the start of therapy. Notably, a persistent effect on VTE events for women with sustained
exposure to tamoxifen over time was also noted. We believe these results suggest that the
initial clustering seen in the first year of use may represent other pre-existing risk factors in
addition to risk contributed by tamoxifen. VTE is a serious life threatening condition with
significant morbidity and mortality [24,25]. Observations from this study, therefore, have
implications for breast cancer treatment, since enhanced ability to identify determinants
which contribute to early VTE events in women on tamoxifen would support
individualization of therapy with less stringent follow-up requirements for women at lower
risk, thereby decreasing frequency of tamoxifen-induced occurrence of this potentially life-
threatening complication in those with breast cancer.
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Fig. 1.
Cumulative incidence of VTE in the first five years by quartile of tamoxifen duration This
plot demonstrates the early clustering of events associated with early discontinuation of
tamoxifen.
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Table 1
Patient characteristics.
Characteristic Classification % (Number)
Age (Years) 0–29 0.3 (9/3572)
(Median 62) 30–49 21.0 (750/3572)
50–59 23.8 (850/3572)
60–69 24.7 (882/3572)
70–79 21.0 (751/3572)
80+ 9.2 (330/3572)
Body mass index (kg/m2) (Median 28.6) Underweight: < 18.5 1.2% (34/2866)
Normal: 18.5 – 24.9 25.4% (729/2866)
Overweight: 25.0 – 29.9 31.6% (906/2866)
Obese: 30.0 – 39.9 34.3% (983/2866)
Extremely Obese: ≥ 40.0 7.5% (214/2866)
Blood Pressure (mmHg) (Median 130/76) Normal: SBP <120, DBP <80 23.4% (757/3237)
Prehypertension: SBP 120–139, DBP 80–89 41.5% (1344/3237)
Stage 1 Hypertension: SBP 140–159, DBP 90–99 28.2% (913/3237)
Stage 2 Hypertension: SBP >160, DBP>100 6.9% (223/3237)
LDL (mg/dL) (Median 117) Optimal: <100 31.3% (760/2427)
Near Optimal: 100–129 31.7% (770/2427)
Borderline: 130–159 23.4% (567/2427)
High: 160–189 9.8% (237/2427)
Very High: >190 3.8% (93/2427)
HDL (mg/dL) (Median 54) Low: <40 14.3% (355/2480)
Optimal: 40–60 49.0% (1214/2480)
High: >60 36.7% (911/2480)
Total Cholesterol (mg/dL) (Median 196) Desirable:<200 54.1% (1534/2835)
Borderline: 200–239 30.6% (867/2835)
High: >240 15.3% (434/2835)
Triglyceride (mg/dL) (Median 129) Normal: <150 60.2% (1509/2505)
Borderline-high: 150–199 17.6% (442/2505)
High: 200–499 20.6% (515/2505)
Very high: ≥ 500 1.6% (39/2505)
Statin Use 37.0% (1322/3572)
Diabetes 13.8% (494/3572)
Smoking 41.1% (907/2207)
Hormone Replacement Therapy 17.9% (639/3572)
SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein
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Table 2
Breast cancer stage and treatment, including events of deep vein thrombosis (DVT) or pulmonary embolism
(PE).
Characteristic Classification % (Number)
Breast Cancer Stage Stage 0 14.5% (446/3074)
Stage I 45.4% (1396/3074)
Stage II 32.3% (994/3074)
Stage III 5.7% (174/3074)
Stage IV 2.1% (64/3074)
Treatment (From Cancer Registry) Chemotherapy 26.5% (475/1794)
Surgery 68.7% (1232/1794)
Radiation 53.2% (839/1794)
Median (Number)
Duration of Tamoxifen by Quartile (years) (Overall Median 3.0) Q1 0.5 (893/3572)
Q2 2.1 (893/3572)
Q3 4.1 (893/3572)
Q4 5.1 (893/3572)
Pre-existing event DVT 2.4 (84/3572)
PE 0.4 (15/3572)
Either DVT or PE 2.6 (92/3572)
Post-tamoxifen initiation event DVT 6.8 (237/3572)
PE 3.4 (117/3572)
Either DVT or PE 8.3 (289/3572)
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Table 3
Hazard Ratios for venous events (DVT or PE) adjusting for potential confounders via multivariable Cox
regression analysis.
Hazard Ratio
95% Confidence Interval
P-valueLower Upper
Tamoxifen duration (years)** 1.215 1.105 1.336 <.001
Age linear (years) 1.032 1.020 1.043 <.001
BMI 30+ vs, <25 (kg/m2) 2.778 1.755 4.397 <.001
BMI 25–29 vs. 30+ (km/m2) 2.320 1.479 3.637 <.001
Hospitalizations 4+ vs. none 1.952 1.416 2.691 <.001
Hospitalizations 1–3 vs. none 4.922 3.433 7.058 <.001
Breast Cancer Stage (0–4) 1.383 1.196 1.601 <.001
Diabetes (Y/N) 1.338 0.967 1.851 0.079
HRT use (Y/N) 0.960 0.693 1.330 0.806
Statin use (Y/N) 1.021 0.786 1.326 0.877
DVT, deep vein thrombosis; PE, pulmonary embolism; BMI, body mass index
**
There was no attenuation of effect as covariates were added. Also, a simple time-dependent indicator of being on (vs. off) tamoxifen revealed
similar results
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